AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: OCREVUS (Genentech) (ocrevus.com)
A high-authority, low-bullshit site that prioritizes clinical proof and safety data over generic marketing jargon. The minor fluff present is largely a byproduct of FDA-compliant phrasing requirements. This is as close to a pure signal-to-substance ratio as pharma marketing allows.
Eliminate the repetitive 10-minute injection claim in every H3 heading to improve Information Density; use those slots for specific clinical outcomes instead. Transition the Nurse and PA mentions into full Person Schema within the structured data to close the digital footprint gap. Provide direct ClinicalTrials.gov link identifiers next to the study summaries to remove the final shred of trust theatre. Reduce the use of the word Proven in headings where a specific metric can be used as the primary lead.
The site maintains a remarkably high ratio of substance to fluff, citing specific metrics like the 1656-person trial size and the 9.8% vs 15.2% disability progression differential. While headings like H1 Proven effective are technically fluff by the dictionary definition, they are immediately anchored by specific technical specifications such as T1 gadolinium-enhancing (Gd+) lesions. The only significant density penalty comes from the extreme repetition of administration times (~10-minute and 2-times-a-year) across every single page, which borders on a cognitive-behavioral mantra rather than new information.
A validator checks markup; an AI audit checks comprehension. Start your free one page AI interpretation to see how your structured data is actually interpreted by LLMs.
There is zero drift between the homepage signal and the sub-page substance. The hero section’s promise of a 10-minute injection (OCREVUS ZUNOVO) is meticulously detailed on the Treatment Experience and Results for RMS pages, with clear distinctions made between administration time and total clinic time. The messaging remains clinically consistent, maintaining the same target audience (MS patients) and value proposition (B-cell targeting) throughout the navigation flow.
Move beyond vague agency reporting and visualize your surgical implementation plan. Order an Executive SEO Strategy and stop relying on superficial keyword tracking.
Trust theatre is nearly non-existent due to heavy regulatory oversight. While there is a review_count of 4 on the homepage without direct peer-review links in the same block, the site provides a robust citation list at the bottom of the Safety & Side Effects page, referencing peer-reviewed studies from Neurology and Mult Scler. Performance claims like 450,000+ people are footnoted with a specific temporal anchor of October 2025, providing a verifiable baseline for the claim.
The proof density is high, with a count of over 10 specific evidence instances across the 4 pages, including trial participant counts, average diagnosis years, and percentage-based efficacy results. The ratio of unsubstantiated claims to verified proof points is roughly 1:8, which is top-tier for a commercial medical site. Verifiable evidence outweighs vague assertions by a significant margin.
For a high volume editorial domain example, open the Search Engine Journal Semantic HTML audit. View the SEJ Semantic HTML Audit to see how template drift and structural noise impact AI chunking.
The site loses points for utilizing a rigid pharma template and standard industry cliches such as science-driven solutions and breakthrough innovation. The H4 Important Safety Information & Indications block is a legal requirement but also a commodity template fingerprint. However, the value proposition is highly differentiated through the specific mechanism of action (targeting B cells) and the unique administration data provided for OCREVUS ZUNOVO, making it impossible to copy-paste this content onto a competitor.
Authority is exceptionally high. The schema_json reveals Genentech as the parent Organization with a physical address (1 DNA Way, South San Francisco) and a customer service line. Named experts, such as John Kramer, PA, are provided within the context of video content, and the site’s authority is further anchored by third-party study citations and specific FDA-mandated risk disclosures.
The site avoids the standard marketing disconnect by tethering every performance claim to a specific clinical study. For instance, the claim that it cut relapses nearly in half is backed by Study 1 and Study 2 data points (0.016 vs 0.286 lesions). There are no bold claims of success without a corresponding clinical trial or real-world evidence figure.
Medical Devices, Pharma & Biotech BS: OCREVUS (Genentech) (ocrevus.com)
The site perfectly matches the Pharma & Biotech category, utilizing highly regulated MedicalWebPage and Drug schema. The content is heavily structured around clinical trial data, safety indications, and pharmacovigilance, which is mandatory for the industry.
A page with no inbound links is invisible to AI, no matter how strong the content is. Open the Internal Linking Framework Guide to learn how link driven relationships shape retrieval, authority, and entity grouping.
“The BS score of 19 is driven entirely by industry-standard template language and repetitive marketing taglines. The site received 0 points in Semantic Coherence and Identity/Authority due to its flawless technical and messaging alignment. The high substance ratio and verified proof paths prevent it from entering the Moderate BS range.”